Motor Neuron Disease Clinical Trial
Official title:
Effect of Functional Exercise in Patients With Spinal and Bulbar Muscular Atrophy
Background:
-Spinal and bulbar muscular atrophy (SBMA) is an inherited disorder that affects men. People
with SBMA often have weakness throughout the body, including the muscles they use for
swallowing, breathing, and speaking. We do not know if exercise helps or harms people with
SBMA.
Objective:
-To see if a 12-week program of either functional exercise or stretching exercises will
improve strength, function, or quality of life in people with SBMA
Eligibility:
- Participants will be men 18 years of age or older who have genetic confirmation of SBMA.
- They must be able to walk at least 50 feet with or without an assistive device such as a
cane or a walker and stand for 10 minutes without using an assistive device.
- They must have access to a computer with an Internet connection.
Design:
- At the first visit to NIH (2 days), participants will have a medical history taken and
undergo a physical exam. They will also have blood tests and an EKG, and complete
questionnaires about mood, health, and exercise. Tests of muscle strength, balance, and
endurance will also be done.
- Participants who qualify for the study will receive instruction about either
strengthening or stretching exercises. They will do these exercises at home one to three
times a week for 12 weeks.
- They will wear a small activity monitor while they exercise and record their exercise in
a diary.
- At the end of 12 weeks, participants will return to the NIH for 2 days. They will
undergo the same tests as they had on the first visit.
- Participants will receive follow-up phone calls and e-mails during the study and for 4
weeks after the last visit....
Objective: Spinal and bulbar muscular atrophy (SBMA), or Kennedy s disease, is a slowly
progressive, X-linked motor neuron disease for which there is currently no treatment. It is
caused by a mutation in the androgen receptor that results in a polyglutamine repeat
expansion. The role of exercise in motor neuron disease research is debated. Although SBMA is
believed to be primarily a neuronopathy, the potential effect of aberrant androgen receptor
activity on muscle leads exercise to be of uncertain utility in this population. Our
objective is to examine the safety and efficacy of exercise regimens in Kennedy s disease.
Study Population: We aim to enroll 80 men with genetically confirmed Kennedy s disease.
Design: This will be a randomized, evaluator blinded, trial with 25 subjects in each exercise
arm. Following informed consent, the subjects will undergo an initial medical and physical
evaluations followed by a series of neurological tests and blood work over a two-day
outpatient visit at the NIH. The subjects will provide blood work for analysis of hormonal
levels and assessment of any potential muscle damage. On the second day of their visit, the
subjects will be randomized and taught a series of either functional or stretching exercises
that they will engage in as part of the study and control arms, respectively. Following the
baseline visit to NIH, the subjects will be monitored throughout the study with telephone
contacts and other measures including video recording to monitor their progress and
compliance. The subjects will return to the NIH at the end of a 12 week period at which time
the physical and laboratory testing will be repeated. After the 12 week exercise period there
will be a four week period where we will follow-up with the participants by telephone and
e-mail. At the end of the trial all of the subjects will be informed of the study results and
given the opportunity to learn the exercises if they are found to be beneficial.
Outcome Measures: The primary outcome measure used will be the Adult Myopathy Assessment Tool
(AMAT). Secondary outcome measures will involve quantitative muscle analysis (QMA), the Timed
Up and Go (TUG) test, a quality of life measure (SF-36v2TM), adverse event questionnaires, a
Computerized Dynamic Posturography (CDP) assessment of balance, accelerometer measurements of
exercise effort, and progressive height sit-to-stand testing. Several exploratory biomarkers
that may be affected by exercise will be evaluated, including insulin-like growth factor-1
(IGF-1), insulin-like growth factor binding protein 3, testosterone, growth hormone, and
creatine kinase. Beck Depression Inventory (BDI) testing will also be used to determine if
the subjects mood is affected by exercise. Qualitative sub-study questions, international
index of erectile function, Block brief food questionnaire, Aggression Questionnaire,
Activities-specific Balance Confidence (ABC) scale, Fatigue Symptom Inventory, and physical
activity survey measures will also be employed.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02464748 -
Telehealth in Motor Neurone Disease
|
N/A | |
Completed |
NCT00956488 -
Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis
|
Phase 1/Phase 2 | |
Terminated |
NCT00537446 -
Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis
|
N/A | |
Recruiting |
NCT04944940 -
Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
|
||
Recruiting |
NCT03362658 -
Novel MRI Biomarkers for Monitoring Disease Progression in ALS
|
||
Completed |
NCT00714636 -
Cerebrospinal Fluid Repository
|
N/A | |
Completed |
NCT00076687 -
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
|
Phase 2 | |
Completed |
NCT00071435 -
Brain Function in Primary Lateral Sclerosis
|
N/A | |
Completed |
NCT00001220 -
Ultrasound and Videofluoroscopy for Diagnosing Swallowing Disorders
|
N/A | |
Completed |
NCT03487263 -
Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease
|
Phase 1 | |
Enrolling by invitation |
NCT05725759 -
Rehabilitation in SOD1 ALS Treated With Tofersen
|
||
Active, not recruiting |
NCT03811301 -
[BrainConnexion] - Neurodevice Phase I Trial
|
N/A | |
Completed |
NCT02469896 -
A Trial of Tocilizumab in ALS Subjects
|
Phase 2 | |
Completed |
NCT02011204 -
Study of Electrical Impedance Myography (EIM) in ALS
|
N/A | |
Completed |
NCT01495390 -
A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers
|
N/A | |
Completed |
NCT02870634 -
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
|
Phase 1 | |
Recruiting |
NCT06201650 -
Neurofilament Light Chain in Amyotrophic Lateral Sclerosis
|